Across TCGA pan-cancer cohorts, IPO9 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IPO9’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where IPO9 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types IPO9 is over-expressed in tumor.
CCRCC, HNSC, and LSCC are the cancer types where IPO9 tumor–normal differential expression is most reproducible.
mass-spec protein tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IPO9 mass-spec protein (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.